MFC Co., Ltd.
MFC produces 37 MFDS-registered APIs along with key starting materials like TBFA and TPPBr for statin-class drugs.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2008, MFC listed on KOSDAQ in 2024 as an API and key material company. It has registered a total of 37 APIs with Korea's MFDS, meeting KP, USP, EP, and JP pharmacopoeia standards, producing and selling the hypertension/hyperlipidemia drugs Pitavastatin and Rosuvastatin, the chronic bronchitis drug Erdostein, the antiplatelet agent Sarpogrelate, and musculoskeletal drugs Afloqualone, Pelubiprofen, and Camostat. It also handles key materials such as TBFA, a common key starting material (KSM) for statin-class drugs, TPPBr (KSM for Pitavastatin), MRV-1 (a key pharmaceutical intermediate for Rosuvastatin), and PPCA (KSM for the DPP-4 inhibitor diabetes drug Anagliptin), and develops improved new drug materials such as MFC-TM001, MFC-RM001, MFC-GM001, and MFC-EM002 through crystal-form modification.
Products & technology
- TBFACommon key starting material for statin-class drugs
- TPPBrKey starting material for Pitavastatin
- MRV-1Key pharmaceutical intermediate for Rosuvastatin
- Pitavastatin API
- Rosuvastatin Strontium API
- RSVT-3T
- Sulglycotide API
- Trimebutine API
- Afloqualone API
- Pelubiprofen API
- Camostat API
- PPCA/AN1Key starting material for Anagliptin (endocrine disease)
- s-Pantoprazole API
- Erdostein APIChronic bronchitis treatment
- Sarpogrelate APIAntiplatelet agent
- Donepezil HCI API
- Donepezil Base API
- s-Amlodipine Besylate APIHypertension treatment
- Fimasartan API (MFC-FG001)
- Azilsartan API
- Edoxaban APIAnticoagulant
R&D and key agreements
Source: DART corporate disclosureMFC-TM001 · 소화계통 질환 · 개량신약원료 개발 · Salt or crystal-form modification development
MFC-IM001 · 소화계통 질환 · 개량신약원료 개발 · Salt or crystal-form modification development
MFC-RM001 · 순환계통 질환 · 개량신약원료 개발 · Salt or crystal-form modification development
MFC-GM001 · 당뇨병 치료제 · 개량신약원료 개발 · Salt or crystal-form modification development
MFC-EM002 · 항응고제 · 개량신약원료 개발 · Salt or crystal-form modification development
Companies in the same categoryPharma & CDMO
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Founded and listed on KOSDAQ in 2015, Kolmar BioTech is a nonclinical CRO providing efficacy testing for anticancer and metabolic disease drug candidates.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition